Abstract
Non-invasive oxygen saturation (SpO2) is a central vital sign that supports the management of COVID-19 patients. However, reports on SpO2 characteristics are scarce and none has analysed high resolution continuous SpO2 in COVID-19. We provide the first analysis of high resolution SpO2 across the spectrum of COVID-19 disease severity and respiratory support. A total of 367 COVID-19 patients’ recordings, comprising 27K hours of continuous SpO2 data, could be retrieved from patients hospitalized at the Rambam Health Care Campus. Using oximetry digital biomarkers (OBM), we quantified SpO2 characteristics and showed that the percentage of time under 93% oxygen saturation threshold is the best single OBM discriminating between critical and non-critical patients. OBMs traditionally used in the field of sleep medicine research, were informative for assessing the patient’s response to respiratory support. In addition, periodicity and hypoxic burden biomarkers were affected up to several hours before the initiation of the mechanical ventilation. Characteristics from high resolution SpO2 signal may enable to anticipate clinically relevant events, monitoring of treatment response and may be indicative of future deterioration.x
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is partially supported by The Milner Foundation, founded by Yuri Milner and his wife Julia. We are grateful to the Placide Nicod fundation for their financial support (J.S.). We acknowledge the financial support of the Technion Machine Learning and Intelligent Systems center (MLIS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this research was provided by the Rambam HCC institutional review board under IRB #0141-20.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Revised abstract and reformatting
Data Availability
The anonymised database including the waveforms and the clinical data from the COVID-19 patients will be accessible upon reasonable request, which will be individually reviewed by the ethical committee of the Rambam HCC.
